급성 투석의 성능과 전달을 최적화하기 위한 기계 학습 및 인공 지능 알고리즘 (SMART DIALYSIS)
스마트 투석 - 기계 학습 및 인공 지능 알고리즘을 확장하여 급성 투석의 성능과 전달을 최적화합니다.
SMART DIALYSIS - Scaling Machine Learning and Artificial Intelligence AlgoRithms to OpTimize the Performance and Delivery of Acute DIALYSIS.
Hypothesis:
Can the investigators develop and implement Machine Learning and Artificial Intelligence Algorithms into Clinical Information Systems to Optimize the Prescription, Delivery, and Performance of Acute Dialysis?
Objective(s):
- Identify variables surrounding identified Key Performance Indicators that may be used by Machine Learning and Artificial Intelligence algorithms to optimize the prescription and performance of acute dialysis.
- Develop Machine Learning and Artificial Intelligence algorithms to help guide the prescription and delivery of acute dialysis in the development of Clinical Decision Support tools and Best Practice Advisories and create a ML/AI Augmented SMART DIALYSIS Digital Dashboard.
- Implement and evaluate the performance of the developed Machine Learning and Artificial Intelligence algorithms on patient-centered and health economic outcomes.
- Validate and benchmark the performance of the evaluated Machine Learning and Artificial Intelligence algorithms across multiple jurisdictions.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Study Background & Rationale:
Acute dialysis is required in approximately 10-15% of all patients admitted to intensive care units (ICUs). Acute dialysis may take the form of continuous renal replacement therapy (CRRT), intermittent hemodialysis (IHD) or slow-low efficiency dialysis (SLED). Worldwide, CRRT remains the predominant form of acute dialysis, with over 75% of acute dialysis being CRRT.
The application of acute dialysis in the ICU is associated with poor patient outcomes. Despite advances in medical technology and care, mortality remains between 40-60%, which is similar to outcomes observed with severe acute respiratory distress syndrome (ARDS). Additionally, even when patients survive their critical illness, up to 10% of patients require ongoing long-term chronic dialysis therapy. This has a significant effect on the quality of life of survivors of critical illness, as well as important effects on their families, often requiring changes in work and housing status, as well as relocation to sites in closer proximity to dialysis centres. This results in not only significant healthcare and social costs (approximately $100,000/patient/year in Alberta, Canada), but also very important reductions in the health-related quality of lives for these patients. Currently, while evidence exist regarding the optimal initiation of acute dialysis, there is a paucity of evidence to predict timing of modality transition or liberation from this therapy. Using a completely integrated electronic Clinical Information System (eCIS) such as Connect Care (EPIC, Wisconsin, USA) in Alberta, the investigators can develop predictive algorithms that may anticipate patient and acute dialysis needs.
Once, acute dialysis is initiated, several factors may affect kidney recovery following acute dialysis. Intra-dialytic hypotension has been identified as a leading modifiable factor, but unfortunately, one where clinicians have limited capacity to accurately predict. This is an important knowledge gap that must be addressed. It has also been previously identified by our study team as one of the most important key performance indicators (KPI) for acute dialysis, especially in IHD and SLED. For CRRT, filter life has been identified as the most important and studied KPI. Both of these KPIs are currently being utilized by the ongoing QUALITY CRRT and DIALYZING WISELY programs to improve the performance and delivery of acute dialysis to critically ill patients. These two programs have been successfully implemented across Alberta and have established the infrastructure necessary to initiate the next steps in these Continuous Quality Initiatives for acute dialysis, the SMART DIALYSIS program.
Recently, advances in computer and machine processing have led to the 4th industrial revolution featuring the development of smart machines, devices, and learning algorithms that can aid humans in the management of patients and optimize the delivery of healthcare. Machine Learning (ML) and Artificial Intelligence (AI) algorithms have been previously used in medicine, but have only begun their implementation into critical care nephrology.
Current initiatives are primarily focused on pattern recognition and risk prediction. This program will contain 4 distinct phases.
In Phase 1, the investigators will continue work from our QUALITY CRRT and DIALYZING WISELY program and will aim to better understand the landscape surrounding decisions around transitions between acute dialysis modalities, termination, and attempts at liberation from acute dialysis, the incidence of intra-dialytic hypotension, and timing of filter clotting in the ICU.
In Phase 2, the investigators will develop models and subsequent Clinical Decision Support (CDS) tools and/or Best Practice Advisories (BPAs) for clinicians to better predict and manage 1) transitions between acute dialysis therapies, 2) management of intra-dialytic hypotension, 3) prediction of filter life and 4) liberation from acute dialysis. Concurrent with this work, we will work to develop an AI/ML Augmented Acute Dialysis Dashboard (i.e., SMART DIALYSIS Digital Dashboard) embedded within our electronic Clinical Information System (eCIS) to present these KPIs to clinicians.
Phase 3 will look into implementing and evaluating the performance and acceptability of these ML/AI algorithms in clinical practice.
Finally, Phase 4 will take our Alberta-derived results and look to implement and benchmark these across other large healthcare authorities to ensure that the algorithms have been developed and validated appropriately and ethically. These will include partners across Canada, the US, Europe and Australia and New Zealand.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Oleksa G Rewa, MD MSc FRCPC
- 전화번호: 17802633280
- 이메일: rewa@ualberta.ca
연구 연락처 백업
- 이름: Fadi Hammal, MD MSc
- 전화번호: 5879907454
- 이메일: hammal@ualberta.ca
연구 장소
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 2T9
- Foothills Medical Center
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Calgary, Alberta, 캐나다, T1Y 6J4
- Peter Lougheed Center
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Calgary, Alberta, 캐나다, T2V 1P9
- Rockyview General Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Calgary, Alberta, 캐나다, T3M 1M4
- South Health Campus
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Edmonton, Alberta, 캐나다, T5H 3V9
- Royal Alexandra Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Edmonton, Alberta, 캐나다, T6L 5X8
- Grey Nuns Community Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Edmonton, Alberta, 캐나다, T6G-2B7
- University of Alberta Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Edmonton, Alberta, 캐나다, T5R 4H5
- Misericordia Community Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Edmonton, Alberta, 캐나다, T6G-2B7
- Mazankowski Heart Institute
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Fort McMurray, Alberta, 캐나다, T9H 1P2
- Northern Lights Regional Hospital.
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Grand Prairie, Alberta, 캐나다, T8V 4B1
- Grand Prairie Regional Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Lethbridge, Alberta, 캐나다, T1J 1W5
- Chinook Regional Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Medicine Hat, Alberta, 캐나다, T1A 4H6
- Medicine Hat Regional Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
Red Deer, Alberta, 캐나다, T4N 4E7
- Red Deer Regional Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
St. Albert, Alberta, 캐나다, T8N 6C4
- Sturgeon Community Hospital
-
연락하다:
- Oleksa Rewa, MD
- 전화번호: 7802633280
- 이메일: rewa@ualberta.ca
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The study population will comprise critically ill patients admitted to an intensive care unit who require acute renal replacement therapy.
설명
Inclusion Criteria
Patients admitted to an intensive care unit (ICU) who require acute renal replacement therapy, either intermittent or continuous.
Exclusion Criteria
Receipt of renal replacement therapy for less than 24 hours.
Pre-existing end-stage kidney disease.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Critically ill patients requiring acute dialysis
Admitted to an intensive care unit; requiring acute dialysis |
We will include any critically ill patient admitted to an intensive care unit requiring acute dialysis. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Identify Key Performance Indicators that may be used by Machine Learning algorithms.
기간: 12 month
|
Key Performance Indicators |
12 month
|
|
Develop Artificial Intelligence and Machine Learning algorithms
기간: 36 month
|
Artificial Intelligence and Machine Learning algorithms |
36 month
|
|
Evaluate the performance of the developed Artificial Intelligence and Machine Learning algorithms.
기간: 60 month
|
ICU and hospital mortality; Renal Recovery at ICU and hospital discharge and 90 days; ICU and hospital lengths of stay; Hospital Costs |
60 month
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Oleksa G Rewa, MD MSc, University of Alberta
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- Pro00160780
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .